Mersana Therapeutics Shares Stabilize Ahead of Acquisition Finalization

Mersana Therapeutics US59045L1061

Mersana Therapeutics stock continues to trade within a consolidation pattern as investors assess the pending acquisition by Day One Biopharmaceuticals. The shares concluded the most recent session with a marginal decline of 0.55%. Since December 9, the equity has largely moved sideways, reflecting a period of market indecision.

The primary driver for the current share price action is the definitive merger agreement with Day One Biopharmaceuticals. Structured as a tender offer, the deal includes an upfront cash payment plus contingent value rights (CVRs). A closing date around the end of January 2026 is anticipated for the acquisition.